Abstract
The first and only pancreatic cancer market intelligence program to be based on the review of
over 500 longitudinal patient charts.
- Longitudinal patient and physician tracking over 3 years
- Actual clinical activity captured from patient charts, not physician recall
- Patient segmentation by type of pancreatic cancer and line of drug therapy
WWMR expert analysis includes:
- Qualitative analysis of nearly 100 current and future drug treatments
- Thought leader opinions on key unmet medical needs and clinical potential for new mechanisms of
action
- Comprehensive review of clinical literature and industry developments
Program Features:
- Monthly drug treatment data by type of pancreatic cancer (exocrine and endocrine) and line of
therapy, January 2001 to January 2004
- Semi-annual data updates through June 2005
- Drug-treated patient forecasts by patient segment - endocrine and exocrine patients by stage,
through 2013
- Market forecasts by drug class, through 2013
- Product-by-product evaluations of investigational agents
- Incidence, prevalence, and mortality forecasts, through 2013
- Quantitative treatment trend analysis
- Unmet needs analysis
- Disease and current treatment review
Program Benefits:
- Pinpoint the specific patient segments that have high market potential in the next 10 years
- Compare the epidemiology, current treatment patterns, patient demographics, and drug-treated
population forecasts by patient segment
- Target specific patient segments that will benefit most from drugs in the pipeline
- Anticipate upcoming competitors and product licensing opportunities
- Recognize the impact of unique market dynamics - including the potential off-label usage - on
product uptake forecasts
- Develop patient segment-specific and drug class-specific forecasts for the overall market and
for key patient segments
- Understand the characteristics of patients unmet need
Program Deliverables:
- Fully-referenced color report
- Comprehensive interactive appendix
- Semi-annual data updates
| 
View Cart
